Bicara Therapeutics (BCAX) Operating Expenses (2023 - 2026)

Bicara Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 44.16% year-over-year to $60.2 million in Q1 2026; TTM through Mar 2026 was $174.1 million, a 59.98% increase from a year earlier, with the FY2025 full-year figure at $155.6 million, up 88.87% from the prior year.
• Operating Expenses climbed to $60.2 million in Q1 2026 per BCAX's latest filing, from $41.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $60.2 million in Q1 2026 and bottomed at $9.5 million in Q3 2023.
• The 4-year median for Operating Expenses is $26.6 million (2024), against an average of $29.2 million.
• Across the five-year window, Operating Expenses soared 171.81% in 2025 and soared 44.16% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $13.7 million in 2023, then surged by 94.62% to $26.6 million in 2024, then jumped by 54.38% to $41.1 million in 2025, then jumped by 46.5% to $60.2 million in 2026.
• Per Business Quant, the three latest BCAX Operating Expenses figures stand at $60.2 million (Q1 2026), $41.1 million (Q4 2025), and $40.7 million (Q3 2025).